- Home
- MAX vs BCAX Comparison
MAX vs BCAX Comparison
Compare MAX & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAX
- BCAX
- Stock Information
- Founded
- MAX 2014
- BCAX 2018
- Country
- MAX United States
- BCAX United States
- Employees
- MAX N/A
- BCAX N/A
- Industry
- MAX Industrial Machinery/Components
- BCAX
- Sector
- MAX Industrials
- BCAX
- Exchange
- MAX Nasdaq
- BCAX NYSE
- Market Cap
- MAX 582.4M
- BCAX 487.6M
- IPO Year
- MAX 2020
- BCAX 2024
- Fundamental
- Price
- MAX $10.35
- BCAX $9.71
- Analyst Decision
- MAX Strong Buy
- BCAX Strong Buy
- Analyst Count
- MAX 6
- BCAX 7
- Target Price
- MAX $17.92
- BCAX $29.17
- AVG Volume (30 Days)
- MAX 419.3K
- BCAX 684.2K
- Earning Date
- MAX 07-30-2025
- BCAX 08-16-2025
- Dividend Yield
- MAX N/A
- BCAX N/A
- EPS Growth
- MAX N/A
- BCAX N/A
- EPS
- MAX 0.28
- BCAX N/A
- Revenue
- MAX $1,002,364,000.00
- BCAX N/A
- Revenue This Year
- MAX $24.09
- BCAX N/A
- Revenue Next Year
- MAX $11.18
- BCAX N/A
- P/E Ratio
- MAX $37.31
- BCAX N/A
- Revenue Growth
- MAX 148.62
- BCAX N/A
- 52 Week Low
- MAX $7.33
- BCAX $7.80
- 52 Week High
- MAX $20.91
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- MAX 45.90
- BCAX N/A
- Support Level
- MAX $10.05
- BCAX N/A
- Resistance Level
- MAX $11.14
- BCAX N/A
- Average True Range (ATR)
- MAX 0.37
- BCAX 0.00
- MACD
- MAX -0.07
- BCAX 0.00
- Stochastic Oscillator
- MAX 26.43
- BCAX 0.00
About MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.